Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates

Transferred anti-IL 18 monoclonal antibody product to Apollo Therapeutics in July with the approximate $15 million of upfront payment received in AugustDosed first patient in the Phase 2 PEAK... | August 4, 2022

Related Keywords

United States ,Ukraine ,Garry Neil ,Christopher Sullivan ,Chris Brinzey ,Group Study To Evaluate The Safety ,Avalo Therapeutics Inc ,Drug Administration ,Nasdaq ,Astrazeneca ,Apollo Therapeutics Group Limited ,Program Updates ,Apollo Therapeutics ,Leukocyte Adhesion Deficiency Type ,Chief Executive Officer ,Medimmune Limited ,Nasdaq Capital ,Loan Agreement ,Parallel Group Study ,Withdrawal Study ,Consolidated Balance Sheets ,Consolidated Statements ,Private Securities Litigation Reform Act ,Avalo Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Transferred , 8 ,Monoclonal ,Ntibody ,Product ,O ,Apollo ,Herapeutics ,N ,July ,Ith ,The ,Approximate ,Billion ,F ,Upfront ,Payment ,Eceived ,Ugustdosed ,First ,Patient ,Hase ,S Avtx Us05338f2074 ,